In light of these findings, this study aimed to evaluate the antitumor activity and safety of camrelizumab combined with trastuzumab and CapOx as neoadjuvant therapy for patients with HER2-positive G/GEJ adenocarcinoma. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.